How many investments has Novalis Biotech made?

Novalis Biotech has 20 tracked investments.

What stage does Novalis Biotech invest at?

Novalis Biotech invests at the Pre-Seed, Seed, Series A stages.

Where is Novalis Biotech located?

Novalis Biotech is headquartered in Ghent, BE.

Who does Novalis Biotech co-invest with?

Novalis Biotech most often shares deals with Navigare Ventures, OCCIDENT, Pantera Capital, among 9 tracked co-investors.

Novalis Biotech

Venture capital

Ghent · Pre-Seed–Series A · 9 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Novalis Biotech invests early in life sciences companies building enabling technologies. It favors capital-light platform technologies and close, early engagement with customers. Priority focus areas include innovative research and manufacturing tools, bioinformatics, genomics, diagnostics, and digital health. The firm targets pre-seed through Series A startups, often coming in at the point of incorporation, and supports their growth by providing funding, sharing professional and academic connections, and helping shape business strategy to create value for all stakeholders.

Invests inAI & Machine Learning Biotech Digital Health FoodTech Healthtech Medical Devices Belgium Europe France Germany Netherlands Portugal Switzerland United States

Source: firm website, verified Aug 3, 2026.

Stage

Pre-Seed–Series A

Ghent, BE

Instruments

Equity

Founded

2018

Tracked investments

Team · 9 people

from the firm's website & public directories

Jan Van den Berghe· Founder· Cranbrook, England, United Kingdomin

Jan Van den Berghe co-founded Novalis Biotech Incubation with Wim. An entrepreneur in the food and biotech sectors, he trained as a bio-engineer and previously worked as a senior consultant at the Boston Consulting Group and as an independent strategy consultant. He co-founded and served as director of Genohm, which Agilent Technologies acquired in 2018, and holds an MBA from INSEAD and a Master in General Management from Vlerick Management School.

j•••@noval.isreveal

Wim Van Criekinge· Founder, Novalis Biotech Incubation· Ghent, Belgiumin

Wim Van Criekinge holds a PhD and is a tenured professor of computational genomics and bioinformatics at Ghent University, where he founded and leads the BIOBIX lab and the NXTGNT core sequencing facility. Together with Jan, he co-founded Novalis Biotech Incubation, and he has co-founded biotech startups including Devgen and Genohm. He currently serves as CSO of MDxHealth, a public biotech company focused on uro-oncology, and holds several biotech startup board seats. He earned a Master's in Chemical Engineering and a PhD in Molecular Biology (1998) from the University of Ghent.

w•••@noval.isreveal

Kjell Mortier· Fund Manager· Ghent Metropolitan Areain

Kjell Mortier (Pharm., PhD) is a Fund Manager at Novalis. He has around 20 years of experience in the biotech industry across scientific roles in large pharma and CDMO companies, including work on bioanalytical and immunogenicity aspects of (pre-)clinical programs at Ablynx (now part of Sanofi) and CMC-analytical support and technology evaluation at the CRO Eurofins. He also holds a certification in financial analysis from EHSAL Management School.

k•••@noval.isreveal

Jaroslav Belotserkovsky· Investment Manager· Leuven, Flemish Region, Belgiumin

Jaroslav Belotserkovsky holds a master's in molecular genetics from the University of Witwatersrand in South Africa and a PhD from Stockholm University in Sweden. His background spans life sciences, health technology, entrepreneurship, and management, including prior roles as an Innovation Manager at KU Leuven, a part-time position in the Department of Oncology, and work on an independent health-tech startup project.

j•••@noval.isreveal

Bart Rossel· Scientific Advisor and Advisory Board Member, Novalis Biotech Incubation Fund; Supervisory Board Member of Novalis

Bart Rossel is a bio-engineer by training who has worked in the agro and life science sectors and held several management roles. In 2002, he and his team acquired the pharmaceutical company Oystershell Laboratories, which they sold to Gilde Buy Out Partners in 2017. He holds several patents and authored a book about insects.

Cedric Bogaert· Entrepreneur in Residence· Ghent, Flemish Region, Belgiumin

Cedric Bogaert is an Entrepreneur in Residence at Novalis Biotech, currently managing myNEO. His background includes epigenomic research at UGent and immunovaccine development research at VUB. He previously worked as a pricing architectural lead at Accenture.

Kathleen Van den Berghe· Member of the Supervisory Board· Tervuren, Flemish Region, Belgiumin

Kathleen Van den Berghe serves on the Supervisory Board of Novalis. She has over 20 years of professional experience as a consultant, entrepreneur, employee, and employer across a wide range of industries, with international work on multiple continents. Her stated areas of expertise include strategy and analysis, construction and industry, and wine and tourism.

Liesbeth Ceelen· CEO of BioLizard· Ghent, Flemish Region, Belgiumin

Liesbeth Ceelen holds a PhD in veterinary sciences and began her career at J&J before moving into biotech and healthcare start-ups and scale-ups, where she worked across operations, quality, project management, scientific leadership, sales, and business development. She is currently CEO of BioLizard, a data analytics and data engineering company. She is involved with the Healthcare Businesswomen's Association and the TOPX Network for Women in Life Sciences, and received the Inspiring 50 STEM award in 2022.

Michael Hengartner· Scientific Advisor and Advisory Board Member, Novalis Biotech Incubation Fund· Zurich, Switzerland

Michael Hengartner serves as a Scientific Advisor and Advisory Board Member for the Novalis Biotech Incubation Fund. He is president of the board of ETH in Zurich, Switzerland, and previously served as rector of the University of Zurich from 2014 to 2019. He earned his PhD in 1994 at the Massachusetts Institute of Technology under Nobel Laureate H. Robert Horvitz, led a research group at Cold Spring Harbor Laboratory until 2001, and became a professor of molecular biology at the University of Zurich, where he also served as dean of the Faculty of Science from 2009 to 2014.

Founder mafia

3 people who came through Novalis Biotech went on to found or lead other companies.

Wim Van CriekingeFounder, Novalis Biotech IncubationFounded Lizard +1 Liesbeth CeelenCEO of BioLizardFounded Lizard Cedric BogaertEntrepreneur in ResidenceFounded myNEO Therapeutics

What they invest in

from 17 of 20 portfolio companies

Biotech ×10Healthtech ×10Medical Devices ×8Deep Tech ×7AI & Machine Learning ×6Digital Health ×5Hardware ×2Advanced Manufacturing ×1

HQs:Belgium×2United States×2Switzerland×1Germany×1France×1

Investments · 20 tracked

founders shown can be your intro path

Trincetrincebio.com in✓ verified

Trince is a Ghent University spin-off developing photoporation technology for physical transfection of cells as an alternative to viral vectors and electroporation.

BiotechDeep TechMedical DevicesGent, BE

Philip

Co-investorsQbic Fund

Alithea Genomicsalitheagenomics.com in 𝕏

Alithea Genomics develops extraction-free, high-throughput RNA sequencing kits and workflows, including massively multiplexed bulk RNA-seq and plate-based single-cell RNA-seq, that skip RNA isolation and support up to 384 or 1536-well library preparation.

BiotechDeep TechHealthtechLausanne, CH

Co-investorsKickfund

Altavoaltavo.eu

Altavo develops non-invasive silent speech technology using RF sensing and artificial intelligence to help patients who have lost their voice regain natural-sounding speech.

AI & Machine LearningDeep TechMedical DevicesDresden, DE

Rudolf

Co-investorsOCCIDENT

C-mo Medical Solutionsc-mo.solutions in

C-mo develops an automated wearable device that records and analyzes cough patterns in real-time for continuous patient monitoring.

Digital HealthHealthtechMedical Devices

Carroucellcarroucell.com in

Carroucell develops microcarrier technology for cell and gene therapy applications, enabling cost-effective bioproduction and cell amplification.

BiotechDeep TechMedical DevicesGrenoble, FR

Tarek Fathallah

Cergentiscergentis.com in

Cergentis provides genetic characterization and quality control services built on its Targeted Locus Amplification (TLA) technology platform, supporting the development of advanced therapies for pharma and biotech clients.

BiotechDeep TechHealthtech

Clouds of Care NVcloudsofcare.com in

Clouds of Care develops EEG and electrophysiology-based digital health technology and software (including FDA-cleared/CE-marked SaMD) to provide meaningful endpoints for clinical development in CNS disorders such as epilepsy and sleep disorders.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Docdoc.ai

HealthtechBoise, US

Hassinger David(Executive Officer)

Co-investorsComet Labs Pantera Capital

Enzyreenzyre.com

Enzyre develops the ENZYSYSTEM, a near-patient blood coagulation testing platform consisting of a blood sampling device, a single-use microfluidic cartridge with reagents, and a reusable processor that measures enzymatic activity in the coagulation cascade and transfers results to the cloud via a mobile app.

BiotechDigital HealthMedical Devices

Fertigafertiga.com in

Fertiga is a biotech spin-off from UZ Brussel and Vrije Universiteit Brussel that develops the Aurora niPCT, a non-invasive diagnostic test analysing the cumulus cells surrounding oocytes to rank egg quality and identify the embryo with the highest chance of a live birth.

BiotechDigital HealthFemTech

Graphealgrapheal.com in

Grapheal develops graphene-based biosensors, including PFAST, a field-deployable device for fast, real-time detection of ultra-trace PFAS ("forever chemicals") in water.

CleantechDeep TechHardware

H42 Inc

US company developing an epigenetic clock and diagnostics, providing multiple biological readouts from a single assay, with applications in rheumatoid arthritis, colorectal cancer screening, and skin-age.

Lizardlizard.bio in

BioLizard provides data analytics and AI solutions that turn biomedical and scientific data into insights for pharma and biotech organizations.

AI & Machine LearningBiotechHealthtech

Modalitymodality.ai

Modality.AI develops an AI-based multimodal assessment platform that uses app-collected data to help diagnose and monitor neurodegenerative diseases such as ALS.

AI & Machine LearningDigital HealthHealthtechMedical Devices

David Suendermann-Oeft(Co-founder & CEO)David Pautler(Co-founder & CTO)

Co-investorsCARELA Holding GmbH Lair East Labs

myNEO Therapeuticsmyneotx.com in

myNEO develops the ImmunoEngine platform, a modular suite of AI-driven technologies for immune target discovery, prioritization, and optimization, covering personalized neoantigen discovery, codon optimization, construct design, ADA risk prediction, and epitope screening.

AI & Machine LearningBiotechHealthtech

Ohmxohmx.bio inOct 2014

Evanston, US

THOMAS MEADE(Director)CHARLES PENNINGTON(CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF ISSUER)Scott Hall(Director)Brian Dyson(Director)Thomas Meade(Director)Peter L. Dyson(Director)

pEGGy BV

Belgian food technology company developing novel solutions for the egg hatching sector; Novalis is a founding investor.

Rarity Bioscienceraritybioscience.com in

Rarity Bioscience develops ultra-sensitive mutation detection assays based on its patented superRCA dual-RCA technology, which amplifies single mutated DNA molecules into fluorescent particles for detection on standard flow cytometers.

BiotechDeep TechHealthtech

Co-investorsNavigare Ventures

Rheavitarheavita.com in

RheaVita develops the RheaLyo continuous, controlled GMP-ready freeze-drying (lyophilization) technology for high-value biologics such as drugs and vaccines.

Advanced ManufacturingBiotechHardware

Co-investorsPMV

RheumaFinderrheumafinder.ai in

RheumaFinder is an AI-powered application that analyzes CT images to detect structural bone lesions in the sacroiliac joints, intended to support radiologists in identifying patients with rheumatic disease.

AI & Machine LearningHealthtechMedical Devices

Portfolio news

latest coverage across their companies

Ingenix raises €13M led by Sofinnova to scale Modality Fusion AI — Sofinnova Partners

Modality · sofinnovapartners.com · Jun 3, 2026

Frequently asked questions

How many investments has Novalis Biotech made?: Novalis Biotech has 20 tracked investments.
What stage does Novalis Biotech invest at?: Novalis Biotech invests at the Pre-Seed, Seed, Series A stages.
What sectors does Novalis Biotech focus on?: Novalis Biotech focuses on AI & Machine Learning, Biotech, Digital Health, FoodTech, Healthtech, Medical Devices.
Where is Novalis Biotech located?: Novalis Biotech is headquartered in Ghent, BE.
Who does Novalis Biotech co-invest with?: Novalis Biotech most often shares deals with Navigare Ventures, OCCIDENT, Pantera Capital, among 9 tracked co-investors.

Images

Similar investors

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Snatched Ventures

Snatched Ventures is a San Francisco-based early-stage venture capital firm backing DeepTech startups focused on sustainable innovation and operational transformation. It is led by a two-GP team combining corporate development and institutional investment management experience.

Rockies Venture Club

Rockies Venture Club is an angel investor network of 100+ active members focused on Seed to Series A opportunities, offering due diligence, syndication nationwide, and educational programming for investors and entrepreneurs.

$100K – $500K

Qbic Fund

Qbic is an inter-university venture capital fund that turns technological breakthroughs from its partner universities, research institutes and hospitals into sustainable businesses.

MaRS

MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.